Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5790926 | 0.89 | HDAC1 (0.46) | HDAC1JAK2 | |
| SCHEMBL5956496 | 0.86 | HPGD (0.50) | TGFBR1 | |
| SCHEMBL5907501 | 0.82 | HDAC1 (0.47) | HDAC1TGFBR1MAPKAPK2JAK2JAK3 | |
| SCHEMBL5956591 | 0.81 | WNT3A (0.45) | HDAC1 | |
| SCHEMBL5956509 | 0.80 | IRAK4 (0.41) | TGFBR1 | |
| SCHEMBL5956490 | 0.79 | WNT3A (0.39) | HDAC1TGFBR1 | |
| SCHEMBL5956662 | 0.79 | LOXL2 (0.55) | TGFBR1 | |
| SCHEMBL5956479 | 0.78 | TGFBR1 (0.57) | TGFBR1CNR2 | |
| SCHEMBL5956440 | 0.78 | WNT3A (0.43) | HDAC1DYRK1A | |
| SCHEMBL5956502 | 0.78 | PRKAB2 (0.47) | HDAC1TGFBR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | DODIC NERINA | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | SMAD2, SMAD3, ALK | HDAC1 1275/4885TGFBR1 7/4885MAPKAPK2 32/4885 |
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | HDAC1 1234/4885TGFBR1 3/4885MAPKAPK2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.